###begin article-title 0
Transactivation and growth suppression by the gut-enriched Kruppel-like factor (Kruppel-like factor 4) are dependent on acidic amino acid residues and protein-protein interaction
###end article-title 0
###begin p 1
To whom correspondence should be addressed at: Department of Medicine, Ross 918, The Johns Hopkins University School of Medicine, 720 Rutland Avenue, Baltimore, MD 21205, USA. Tel: +1 410 955 9691; Fax: +1 410 955 9677; Email: vyang@welchlink.welch.jhu.edu
###end p 1
###begin p 2
###xml 924 925 924 925 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 955 962 955 962 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 235 241 <span type="species:ncbi:10090">murine</span>
Gut-enriched Kruppel-like factor (GKLF or KLF4) is a pleiotropic (activating and repressive) transcription factor. This study characterizes the mechanisms of transactivation by GKLF. Using a GAL4 fusion assay, the activating domain of murine GKLF was localized to the 109 amino acid residues in the N-terminus. Site-directed mutagenesis showed that two adjacent clusters of acidic residues within this region are responsible for the activating effect. Transactivation by GKLF involves intermolecular interactions as demonstrated by the ability of wild-type, but not mutated, GKLF to compete with the N-terminal activation domain. In addition, wild-type adenovirus E1A, but not a mutated E1A that failed to bind p300/CBP, inhibited transactivation by the N-terminal 109 amino acids of GKLF, suggesting that p300/CBP are GKLF's interacting partners. A physical interaction between GKLF and CBP was demonstrated by glutathione-S-transferase pull-down and by in vivo co-immunoprecipitation experiments. We also showed that the two acidic amino acid clusters are essential for this interaction, since GKLF with mutations in these residues failed to co-immunoprecipitate with CBP. Importantly, the same mutations abrogated the ability of GKLF to suppress cell growth as determined by a colony suppression assay. These studies therefore provide plausible evidence for a structural and functional correlation between the transactivating and growth-suppressing effects of GKLF.
###end p 2
###begin title 3
INTRODUCTION
###end title 3
###begin p 4
###xml 159 160 159 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c1">1</xref>
###xml 355 356 355 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c2">2</xref>
###xml 357 358 357 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c6">6</xref>
###xml 543 544 543 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c7">7</xref>
###xml 545 546 545 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c8">8</xref>
###xml 558 559 558 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c9">9</xref>
###xml 560 562 560 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c10">10</xref>
###xml 584 586 584 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c11">11</xref>
###xml 587 589 587 589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c13">13</xref>
###xml 727 729 727 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c14">14</xref>
###xml 730 732 730 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c15">15</xref>
###xml 740 742 740 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c16">16</xref>
###xml 743 745 743 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c18">18</xref>
###xml 758 760 758 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c19">19</xref>
###xml 971 973 971 973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c20">20</xref>
###xml 974 976 974 976 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c21">21</xref>
Eukaryotic transcription factors are modular proteins that depend on distinct domains for their functions such as DNA binding and modulation of transcription (1). Various structural motifs have been described that are involved in DNA binding and/or protein dimerization. Examples include the zinc finger, basic helix-loop-helix and leucine zipper motifs (2-6). Many transcription factors also contain distinct domains for the transcriptional activation or repression of target genes. Activation domains, for example, can be rich in glutamine (7,8), proline (9,10) or acidic residues (11-13). Adding to the complexity of transcriptional regulation is the recent identification of a group of co-activator proteins, such as p300 (14,15), CBP (16-18) and P/CAF (19). Collectively, these proteins exhibit a broad spectrum of activities including interaction with sequence-specific DNA-binding proteins and the basal transcriptional machinery, as well as chromatin remodeling (20,21).
###end p 4
###begin p 5
###xml 87 89 87 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c22">22</xref>
###xml 158 159 158 159 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 160 161 160 161 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 190 194 190 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GKLF</italic>
###xml 258 260 258 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c23">23</xref>
###xml 261 263 261 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c25">25</xref>
###xml 279 281 279 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c25">25</xref>
###xml 282 284 282 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c26">26</xref>
###xml 322 324 322 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c27">27</xref>
###xml 331 339 331 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 354 358 354 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GKLF</italic>
###xml 479 481 479 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c23">23</xref>
###xml 592 594 592 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c23">23</xref>
###xml 693 700 693 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 870 872 870 872 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c28">28</xref>
The gut-enriched Kruppel-like factor (GKLF; also called Kruppel-like factor 4 or KLF4; 22) is a recently identified Kruppel-type transcription factor with 3 C2H2 zinc fingers. Expression of GKLF is enriched in epithelial cells of the gastrointestinal tract (23-25) and the skin (25,26), and in vascular endothelial cells (27). The in vitro expression of GKLF is temporally associated with a growth-arrested state, such as that induced by contact inhibition or serum deprivation (23). In addition, constitutive GKLF production in transfected cells resulted in the inhibition of DNA synthesis (23). These results suggest that GKLF is a negative regulator of cell growth. The significance of the in vivo function of GKLF is heightened by the fact that expression of its gene is developmentally regulated and is down-regulated in a rodent model of intestinal tumorigenesis (28). Taken together, these studies suggest that GKLF may have a potentially important function in regulating proliferation and differentiation of specific epithelial and endothelial tissues.
###end p 5
###begin p 6
###xml 46 48 46 48 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c23">23</xref>
###xml 88 90 88 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c29">29</xref>
###xml 175 177 175 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c30">30</xref>
###xml 189 191 189 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c31">31</xref>
###xml 313 315 310 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c32">32</xref>
###xml 316 318 313 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c33">33</xref>
###xml 344 346 341 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c34">34</xref>
###xml 347 349 344 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c35">35</xref>
###xml 445 447 436 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c32">32</xref>
###xml 448 450 439 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c33">33</xref>
###xml 603 605 594 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c24">24</xref>
###xml 606 608 597 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c25">25</xref>
###xml 609 611 600 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c27">27</xref>
###xml 612 614 603 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c36">36</xref>
###xml 686 688 677 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c36">36</xref>
###xml 855 861 846 852 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1A1</italic>
###xml 863 865 854 856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c37">37</xref>
###xml 866 868 857 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c38">38</xref>
###xml 926 928 917 919 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c36">36</xref>
###xml 929 931 920 922 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c39">39</xref>
The amino acid sequences of the zinc fingers (23) and the nuclear localization signals (29) of GKLF are closely related to two other Kruppel-like transcription factors, LKLF (30) and EKLF (31). Among the three, EKLF is the most extensively characterized. EKLF is essential for expression of the beta-globin gene (32,33) and for erythropoeisis (34,35). It activates the beta-globin gene by binding to a CACCC element in the beta-globin promoter (32,33). Because of the high degree of homology between the zinc finger regions of GKLF and EKLF, GKLF has been shown to bind to the same or similar elements (24,25,27,36). However, GKLF also binds DNA sequences other than the CACCC element (36). The basic transcription element (BTE), found in the promoter of a highly conserved family of genes encoding the cytochrome P450 drug-metabolizing enzymes including CYP1A1 (37,38), for example, is a high-affinity binding site for GKLF (36,39).
###end p 6
###begin p 7
###xml 87 93 87 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1A1</italic>
###xml 142 148 142 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1A1</italic>
###xml 186 188 186 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c39">39</xref>
###xml 317 323 317 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP1A1</italic>
###xml 325 327 325 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c39">39</xref>
###xml 515 517 515 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c27">27</xref>
###xml 603 605 603 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c24">24</xref>
###xml 606 608 606 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c25">25</xref>
###xml 609 611 609 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c36">36</xref>
###xml 699 701 699 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c25">25</xref>
###xml 702 704 702 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c27">27</xref>
A recent examination of the relationship between GKLF and the promoter activity of the CYP1A1 gene indicates that GKLF is a suppressor of the CYP1A1 promoter in a BTE-dependent fashion (39). It does so by competing with the binding of Sp1 to BTE and by physically interacting with Sp1, which is a potent activator of CYP1A1 (39). Both effects seem to be mediated by the zinc fingers of GKLF. Another study showed that GKLF possesses an intrinsic repression domain in a region of protein preceding the zinc fingers (27). In different situations, however, GKLF can be a potent activator of transcription (24,25,36). Moreover, the N-terminal region of GKLF was shown to confer the activating function (25,27). These observations indicate that GKLF is a pleiotropic protein with a dual activity in modulating transcription. The present study examines in detail the mechanisms by which GKLF activates transcription and shows that such mechanisms are complex, requiring two clusters of acidic amino acid residues within GKLF for full activity. The same amino acid residues proved to be indispensable for the interaction of GKLF with the co-activator CBP and for the ability of GKLF to suppress cell growth. Our study therefore demonstrates an important association between two primary biological activities of GKLF, that of transcription activation and that of growth suppression.
###end p 7
###begin title 8
MATERIALS AND METHODS
###end title 8
###begin title 9
Plasmid DNA constructs
###end title 9
###begin p 10
###xml 106 108 106 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c40">40</xref>
###xml 155 157 155 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c23">23</xref>
###xml 158 160 158 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c29">29</xref>
###xml 161 163 161 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c36">36</xref>
###xml 164 166 164 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c39">39</xref>
###xml 474 476 474 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c29">29</xref>
###xml 477 479 477 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c36">36</xref>
###xml 480 482 480 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c39">39</xref>
###xml 576 578 576 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c29">29</xref>
###xml 579 581 579 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c36">36</xref>
###xml 582 584 582 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c39">39</xref>
###xml 819 822 819 822 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Sma</italic>
###xml 824 827 824 827 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Apa</italic>
###xml 856 858 856 858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c23">23</xref>
###xml 46 52 <span type="species:ncbi:10090">murine</span>
The expression construct encoding full-length murine GKLF cloned in the mammalian expression vector PMT3 (40), PMT3-GKLF(1-483), was described previously (23,29,36,39). Expression constructs with truncation mutations were generated by deleting various segments of the GKLF reading frame with the appropriate restriction endonucleases. They included PMT3-GKLF(1-401), containing the N-terminal region including the nuclear localization signal but excluding the zinc fingers (29,36,39); PMT3-GKLF(350-483), containing the nuclear localization signal and the three zinc fingers (29,36,39); and PMT3-GKLF(145-483), which had a deletion of the N-terminal 144 amino acid residues of GKLF. In addition, a mutant construct with an internal deletion between amino acid residues 158 and 349 was generated by deleting an internal SmaI-ApaI fragment of the GKLF cDNA (23).
###end p 10
###begin p 11
###xml 199 200 199 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd222f1">1</xref>
###xml 483 485 483 485 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1b</sub>
###xml 520 522 520 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c36">36</xref>
###xml 617 619 617 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c41">41</xref>
###xml 695 697 695 697 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c36">36</xref>
Constructs of GKLF with point mutations were generated from PMT3-GKLF(1-483) using the QuickChange site-directed mutagenesis kit from Stratagene (La Jolla, CA). Two such mutants were generated (Fig. 1C). One substituted valine residues for three glutamate residues at amino acid positions 93, 95 and 96 [PMT3-GKLF(E93/95/96V)] and the other substituted valine residues for three aspartate residues at positions 99, 102 and 104 [PMT3-GKLF(D99/102/104V)]. The reporter plasmid, TDAx2-E1bTATALUC, was described previously (36). This construct contained a luciferase (LUC) reporter driven by the adenovirus E1b TATA box (41) linked to two tandem copies of the empirically derived GKLF-binding site (36).
###end p 11
###begin p 12
###xml 171 173 171 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c42">42</xref>
###xml 174 176 174 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c43">43</xref>
###xml 349 350 349 350 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 357 359 357 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c44">44</xref>
###xml 865 867 857 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c45">45</xref>
###xml 982 984 974 976 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c46">46</xref>
###xml 1010 1012 1002 1004 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c47">47</xref>
###xml 1067 1068 1059 1060 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 1271 1273 1263 1265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c45">45</xref>
###xml 1297 1299 1289 1291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c47">47</xref>
###xml 75 80 <span type="species:ncbi:4932">yeast</span>
###xml 737 740 <span type="species:ncbi:12814?0.7497633322814768|species:ncbi:11886?0.2234143262858946|species:ncbi:12331?0.0041022404544020195">RSV</span>
###xml 780 783 <span type="species:ncbi:12814?0.7497633322814768|species:ncbi:11886?0.2234143262858946|species:ncbi:12331?0.0041022404544020195">RSV</span>
###xml 800 803 <span type="species:ncbi:12814?0.7497633322814768|species:ncbi:11886?0.2234143262858946|species:ncbi:12331?0.0041022404544020195">RSV</span>
###xml 915 918 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 928 931 <span type="species:ncbi:12814?0.7497633322814768|species:ncbi:11886?0.2234143262858946|species:ncbi:12331?0.0041022404544020195">RSV</span>
Chimeric plasmids fusing the DNA-binding domain (amino acids 1-147) of the yeast transcription factor GAL4 to various regions of GKLF were generated in the plasmid pGALO (42,43), a kind gift of Dr Chi V. Dang. The junctions between the GAL4 and GKLF sequences in all constructs were confirmed to be in-frame by sequencing. The reporter construct, pG5TKLUC (44), also from Dr Dang, contains the luciferase gene driven by the herpes simplex virus TK promoter linked to five tandem copies of the GAL4 binding site. Two point mutants affecting the acidic domains were generated from the GAL4(1-147) and GKLF(1-109) fusion construct using the QuickChange mutagenesis kit as described above. The wild-type adenovirus E1A-containing construct, RSV-E1A12S, and the two mutant constructs, RSV-E1ADeltaCR1 and RSV-E1ADeltaCR2, were generously provided by Dr Tony Kouzarides (45). The expression plasmids containing p300/CBP, CMV-p300 and RSV-CBP were kindly provided by Drs Andrew B. Leiter (46) and Richard H. Goodman (47), respectively. Fusion constructs between glutathione-S-transferase (GST) and various regions of CBP including GST-CBP1 (amino acids 461-662), GST-CBP2 (amino acids 1621-1877) and GST-CBP3 (amino acids 1990-2441) were kindly provided by Drs Tony Kouzarides (45) and Robert G. Roeder (47).
###end p 12
###begin title 13
Transfection and reporter assays
###end title 13
###begin p 14
###xml 145 147 145 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c23">23</xref>
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c29">29</xref>
###xml 151 153 151 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c36">36</xref>
###xml 154 156 154 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c39">39</xref>
###xml 395 397 389 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c36">36</xref>
###xml 26 41 <span type="species:ncbi:10029">Chinese hamster</span>
Transient transfection of Chinese hamster ovary (CHO) cells by lipofection was performed with CsCl-purified plasmid DNA as described previously (23,29,36,39). A constant amount of DNA of an internal standard, pCMV-SPORT-beta-galactosidase (Life Technologies, Gaithersburg, MD), was used in all reactions. Assays to measure luciferase and beta-galactosidase activities were described previously (36). All luciferase activities were standardized to beta-galactosidase activities in transfected cells.
###end p 14
###begin title 15
Production of recombinant proteins
###end title 15
###begin p 16
###xml 198 214 194 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Escherichia coli</italic>
###xml 390 391 383 384 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d</sc>
###xml 198 214 <span type="species:ncbi:562">Escherichia coli</span>
Fusion proteins between GST and various segments of CBP (GST-CBP1, GST-CBP2 and GST-CBP3), or GST alone, were produced as recombinant proteins in bacteria. Single colonies of the DH5alpha strain of Escherichia coli (Life Technologies) were transformed by the respective plasmid construct and expanded in LB broth containing ampicillin to an optical density of 0.5 at 600 nm. Isopropyl-beta-d-thiogalactopyranodise (1 mM) was then added and incubation continued for an additional 4 h at which time the bacterial pellets were collected by centrifugation. The pellets were resuspended in a lysis buffer containing 20 mM Tris-HCl, pH 8.0, 2 mM EDTA, 1% glycerol, 1 microg/ml each of leupeptin, pepstatin and aprotinin, and sonicated with a Fisher Scientific 50 Sonic Dismembrator at a setting of 5 for 15 s at a time for 10 cycles. After clearing debris by centrifugation, solubilized proteins were stored in aliquots at -80degreesC.
###end p 16
###begin title 17
###xml 29 37 29 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
Synthesis of GKLF protein by in vitro transcription and translation
###end title 17
###begin p 18
###xml 31 33 31 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 230 232 230 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c23">23</xref>
###xml 459 461 435 437 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 298 304 <span type="species:ncbi:9986">rabbit</span>
Full-length GKLF labeled with [35S]methionine was synthesized by the TNT T7 Coupled Reticulocyte Lysate System manufactured by Promega (Madison, WI). Two micrograms of template DNA of GKLF in pBluescript (Stratagene, LaJolla, CA; 23) were incubated in a 50 microl reaction containing 25 microl TNT rabbit reticulocyte lysates, 2 microl TNT reaction buffer, 1 microl amino acid mixture minus methionine, 1 microl RNasin (a ribonuclease inhibitor), 40 microCi [35S]methionine (>1000 Ci/mmol; NEN Life Science Products, Boston, MA) and 1 microl TNT T7 RNA polymerase at 30degreesC for 90 min. An aliquot of the reaction was then resolved by denaturing polyacrylamide gel electrophoresis (PAGE) followed by autoradiography to verify the quality of the synthesized product.
###end p 18
###begin title 19
GST pull-down experiments
###end title 19
###begin p 20
###xml 88 96 88 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 570 571 566 567 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 599 600 591 592 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 725 727 713 715 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 765 773 753 761 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
GST pull-down experiments were performed using GST-CBP fusion proteins or GST alone and in vitro synthesized GKLF. One milligram of solubilized recombinant GST-CBP fusion proteins or GST was mixed with 500 microl glutathione-Sepharose 4B beads (Amersham Pharmacia Biotech, Piscataway, NJ) supplied as a 50% suspension and gently rocked at room temperature for 40 min. The beads were then collected by centrifugation and washed three times with 1.5 ml phosphate-buffered saline (PBS). A binding buffer containing 10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 20 mM KCl, 10 mM MgCl2, 0.5 mM DTT, 10 microM ZnCl2 and 1.2% glycerol was then added to the washed beads to a final volume of 600 microl, followed by the addition of 15 ml of [35S]methionine-labeled GKLF synthesized in vitro. The mixture was gently rocked at 4degreesC for 1 h following which the beads were collected by centrifugation and washed three times with 1 ml PBS containing 0.025% NP-40. Bound proteins were eluted by incubating the washed beads with 10 mM reduced glutathione in 50 mM Tris-HCl, pH 8.0, at 4degreesC for 30 min. The eluant was concentrated by drying in a Speed Vac, resuspended in 3x sample buffer (0.18 M Tris-HCl, pH 6.8, 70 mM EDTA, 6% SDS, 30% glycerol and 0.015% bromophenol blue) and resolved by denaturing SDS-PAGE followed by autoradiography.
###end p 20
###begin title 21
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vivo</italic>
In vivo co-immunoprecipitation experiments
###end title 21
###begin p 22
###xml 232 234 228 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c47">47</xref>
###xml 504 506 496 498 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 1046 1052 1020 1026 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sc-805</italic>
###xml 170 173 <span type="species:ncbi:12814?0.7497633322814768|species:ncbi:11886?0.2234143262858946|species:ncbi:12331?0.0041022404544020195">RSV</span>
###xml 338 344 <span type="species:ncbi:9913">bovine</span>
COS-1 cells were transiently co-transfected by lipofection with 10 microg/10 cm dish each of PMT3-GKLF(1-483), PMT3-GKLF(E93/95/96V), PMT3-GKLF(D99/102/104V) or PMT3 and RSV-CBP tagged with the influenza hemagglutinin (HA) epitope (47) followed by an overnight incubation in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS). Cells were then washed three times with 10 ml methionine-free DMEM and incubated in 3 ml methionine-free DMEM containing 10% FBS and 500 microCi [35S]methionine (>1000 Ci/mmol; NEN Life Science Products) at 37degreesC for 3 h. Cells were then washed three times with 10 ml ice cold PBS and collected by scraping and centrifugation. A modified RIPA buffer (1% NP-40, 0.1% SDS, 0.5% Na deoxycholate, and 1 microg/ml each of leupeptin, pepstatin and aprotinin in PBS) at a volume of 400 microl/10 cm dish was then used to lyse the cells. The metabolically labeled cell extracts were divided into three 125 microl aliquots and incubated with pre-immune serum, anti-GKLF serum or anti-HA IgG (sc-805; Santa Cruz Biotechnology, Santa Cruz, CA) at 4degreesC for 2 h. Sixty microliters of a 50% suspension of protein A-Sepharose CL-4B (Amersham Pharmacia Biotech) were then added and the incubation continued at 4degreesC for 1 h. The beads were collected by centrifugation and washed three times with 1 ml modified RIPA buffer before being resuspended in 3x sample buffer for electrophoresis.
###end p 22
###begin title 23
Colony suppression assays
###end title 23
###begin p 24
###xml 101 103 101 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c48">48</xref>
###xml 119 121 119 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c44">44</xref>
###xml 233 235 233 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c48">48</xref>
Colony suppression assays were performed based on a modification of a previously published protocol (48). Rat1a cells (44) were transfected with PMT3, PMT3-GKLF(1-483), PMT3-GKLF(E93/95/96V) or PMT-GKLF(D99/102/104V) and pBabe Puro (48) which contained a puromycin-resistant gene, at a molar ratio of 40:1. Two days following transfection cells were fed DMEM containing 10% FBS and 0.75 microg/ml puromycin. Two weeks into the puromycin selection resistant colonies were visualized by staining with a 1% methylene blue solution.
###end p 24
###begin title 25
RESULTS
###end title 25
###begin title 26
Transactivation by GKLF depends on two clusters of acidic amino acid residues in its N-terminus
###end title 26
###begin p 27
###xml 156 158 156 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c42">42</xref>
###xml 159 161 159 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c43">43</xref>
###xml 377 378 377 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd222f1">1</xref>
###xml 519 520 519 520 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 527 529 527 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c44">44</xref>
###xml 537 538 537 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd222f1">1</xref>
###xml 662 663 662 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd222f1">1</xref>
###xml 715 725 715 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink">effector 1</italic>
###xml 909 919 909 919 <italic xmlns:xlink="http://www.w3.org/1999/xlink">effector V</italic>
###xml 982 992 982 992 <italic xmlns:xlink="http://www.w3.org/1999/xlink">effector 2</italic>
###xml 1158 1168 1158 1168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">effector 3</italic>
###xml 1196 1206 1196 1206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">effector 4</italic>
###xml 1346 1356 1346 1356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">effector 6</italic>
###xml 339 344 <span type="species:ncbi:4932">yeast</span>
As an initial attempt to localize the domain responsible for the transactivating activity of GKLF, we adopted the previously established GAL4 fusion assay (42,43). We generated eight effector constructs by fusing various regions of the GKLF reading frame outside its zinc fingers to the N-terminal 147 amino acid DNA-binding domain of the yeast transcription factor GAL4 (Fig. 1B). A luciferase reporter driven by the herpes virus thymidine kinase (TK) promoter linked to five tandem copies of the GAL4 binding site [pG5TKLUC (44); Fig. 1A] was used to read out the activating potential of the various regions of GKLF upon co-transfection. The results in Figure 1A show that the N-terminal 329 amino acids of GKLF (effector 1) harbors an activation domain, as evidenced by the significant induction in the luciferase activity in cells co-transfected with this effector when compared to those with the vector (effector V) alone. A deletion in the N-terminal 156 amino acids of GKLF (effector 2) resulted in a complete loss of activating potentials. In contrast, the N-terminal 157 amino acids of GKLF maintained its inducing effect when present in the sense (effector 3) but not in the antisense (effector 4) orientation. Further deletion analysis revealed that the activation domain of GKLF is solely localized to the N-terminal 109 amino acids (effector 6).
###end p 27
###begin p 28
###xml 100 102 100 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c23">23</xref>
###xml 198 200 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c11">11</xref>
###xml 201 203 201 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c13">13</xref>
###xml 392 393 392 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd222f1">1</xref>
###xml 415 416 415 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd222f1">1</xref>
The N-terminal 109 amino acid region of GKLF contains several closely clustered acidic amino acids (23). As acidic residues have previously been shown to be involved in activation of transcription (11-13), we selectively mutagenized two neighboring clusters of acidic residues, one of three glutamates and the other of three aspartates, in the region between amino acid residues 93-104 (Fig. 1C). As seen in Figure 1A, mutation in either cluster in the context of the fusion between GAL4(1-147) and GKLF(1-109) completely abolished the ability of the N-terminal 109 amino acids of GKLF to activate reporter expression. These results strongly suggest that both clusters of acidic residues are involved in mediating transactivation by GKLF.
###end p 28
###begin p 29
###xml 283 285 283 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c36">36</xref>
###xml 333 335 333 335 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1b</sub>
###xml 364 365 364 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd222f2">2</xref>
###xml 386 396 386 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink">effector 1</italic>
###xml 484 494 484 494 <italic xmlns:xlink="http://www.w3.org/1999/xlink">effector V</italic>
###xml 586 596 586 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">effector 2</italic>
###xml 640 650 640 650 <italic xmlns:xlink="http://www.w3.org/1999/xlink">effector 3</italic>
###xml 741 751 741 751 <italic xmlns:xlink="http://www.w3.org/1999/xlink">effector 4</italic>
###xml 859 869 859 869 <italic xmlns:xlink="http://www.w3.org/1999/xlink">effector 5</italic>
###xml 1029 1030 1017 1018 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd222f1">1</xref>
The activation domains of GKLF were verified by co-transfection experiments involving full-length or deleted GKLF constructs cloned in the mammalian expression vector, PMT3, and a luciferase reporter containing two tandem copies of the empirically determined GKLF-binding site (TDA; 36) linked to the adenovirus E1b TATA box (TDAx2-E1bTATALUC). As shown in Figure 2A, full-length GKLF (effector 1) induced the luciferase activity by a mean of 4.3-fold as compared to the PMT3 vector (effector V). The activating effect was abolished in a construct that contained only the zinc fingers (effector 2) or one that had the zinc fingers deleted (effector 3). Moreover, the activating effect was also abolished when the N-terminal 144 amino acids (effector 4) were deleted. In contrast, a construct with an internal deletion between amino acid residues 158 and 349 (effector 5) retained approximately75% of the activity of the full-length construct. These results are therefore consistent with those of the GAL4 fusion assays in Figure 1.
###end p 29
###begin p 30
###xml 356 357 356 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd222f2">2</xref>
###xml 379 380 379 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd222f2">2</xref>
###xml 430 440 430 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">effector 6</italic>
###xml 596 606 584 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink">effector 7</italic>
To verify the preceding findings from the GAL4 fusion assay that the two clusters of acidic residues in the N-terminal 109 amino acids are indeed crucial for GKLF's ability to activate transcription, we generated two point mutants that selectively changed either the three glutamates or three aspartates to valines in the context of full-length GKLF (Fig. 2B). As seen in Figure 2A, conversion of the three glutamates to valines (effector 6) resulted in a significant (approximately75%) reduction in the ability of GKLF to activate transcription. In comparison, mutation of the three aspartates (effector 7) resulted in a total loss of activity. These findings suggest that both clusters of acidic residues are involved in mediating transactivation by GKLF although mutation of the aspartates seems more deleterious than that of the glutamates.
###end p 30
###begin title 31
Transactivation by GKLF involves intermolecular interaction
###end title 31
###begin p 32
###xml 76 78 76 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c29">29</xref>
###xml 115 117 115 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c31">31</xref>
###xml 262 264 262 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c49">49</xref>
###xml 395 397 395 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c31">31</xref>
###xml 514 516 514 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c49">49</xref>
Among members of the subfamily of Kruppel proteins closely related to GKLF (29), EKLF was the earliest identified (31) and probably best characterized. Like GKLF, the transactivation domain of EKLF has previously been localized to its N-terminal 124 amino acid (49). Although it has a different primary amino acid sequence from that of GKLF, this region of EKLF is also rich in acidic residues (31). Moreover, the mechanism of transactivation by EKLF appears to be complex and involves intermolecular interaction (49). We therefore asked the question whether a similar mechanism is also involved in transactivation by GKLF.
###end p 32
###begin p 33
###xml 118 125 118 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 182 184 182 184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c49">49</xref>
###xml 421 422 421 422 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 654 655 654 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd222f3">3</xref>
###xml 697 709 697 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink">competitor 1</italic>
###xml 788 789 788 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd222f3">3</xref>
###xml 847 859 847 859 <italic xmlns:xlink="http://www.w3.org/1999/xlink">competitor V</italic>
###xml 883 884 883 884 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd222f3">3</xref>
###xml 975 987 975 987 <italic xmlns:xlink="http://www.w3.org/1999/xlink">competitor 2</italic>
###xml 994 995 994 995 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd222f3">3</xref>
###xml 1055 1067 1055 1067 <italic xmlns:xlink="http://www.w3.org/1999/xlink">competitor 3</italic>
###xml 1074 1075 1074 1075 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd222f3">3</xref>
###xml 1320 1333 1320 1333 <italic xmlns:xlink="http://www.w3.org/1999/xlink">competitors 4</italic>
###xml 1338 1339 1338 1339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">5</italic>
###xml 1432 1433 1432 1433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd222f3">3</xref>
The possibility of intermolecular interaction as part of the mechanism for transactivation of GKLF was examined by an in vivo competition assay similar to that described previously (49). In this assay an expression construct containing full-length GKLF was introduced by transfection in gradually increasing amounts relative to the GAL4 fusion construct containing the N-terminal 109 amino acids of GKLF along with the pG5TKLUC reporter. If transactivation by GKLF requires the participation of interacting molecules, the presence of full-length GKLF in excess might 'squelch' the activating ability of its own transactivation domain. As shown in Figure 3, increasing amounts of full-length GKLF (competitor 1) competed for the activating effect of GAL4-GKLF(1-109) on the reporter (Fig. 3B) in a dose-dependent fashion, whereas the vector alone (competitor V) failed to do so (Fig. 3A). Moreover, the competing effect of GKLF was mediated by the N-terminal 401 amino acids (competitor 2; Fig. 3C) but not by the sequence between amino acids 145 and 483 (competitor 3; Fig. 3D). This indicates that the N-terminal 144 amino acids of GKLF compete for an interacting molecule(s) involved in transactivation. Significantly, both mutant constructs with substitution in the two acidic clusters within the N-terminus of GKLF (competitors 4 and 5) failed to compete for the activating effect of the N-terminal transactivation domain (Fig. 3E and F). These results suggest that intermolecular interaction is responsible, at least in part, for the transactivation by GKLF. Moreover, the same two clusters of acidic amino acids in the N-terminus necessary for GKLF's transactivating effect are involved in such interaction.
###end p 33
###begin title 34
Transactivation by GKLF involves p300/CBP
###end title 34
###begin p 35
###xml 213 215 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c50">50</xref>
###xml 216 218 216 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c52">52</xref>
###xml 237 239 237 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c53">53</xref>
###xml 610 612 610 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c14">14</xref>
###xml 613 615 613 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c15">15</xref>
###xml 707 714 707 714 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 838 839 838 839 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd222f4">4</xref>
###xml 857 869 857 869 <italic xmlns:xlink="http://www.w3.org/1999/xlink">competitor 1</italic>
###xml 1069 1081 1065 1077 <italic xmlns:xlink="http://www.w3.org/1999/xlink">competitor 3</italic>
###xml 1167 1168 1163 1164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd222f4">4</xref>
###xml 1271 1283 1263 1275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">competitor 2</italic>
###xml 1341 1342 1333 1334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd222f4">4</xref>
The recently described p300/CBP family of co-activators have been implicated in the regulation of transcription by modifying chromatin structure and by physically interacting with a host of transcription factors (50-52), including EKLF (53). An often employed strategy to study whether p300/CBP are involved in mediating the function of a transcription factor is to examine the effect of the adenovirus E1A oncoprotein on the activity of that factor. E1A is a multifunctional viral protein that modulates transcription of cellular genes by interacting with several key cellular proteins that include p300/CBP (14,15). To determine whether E1A also modulates the transactivating effect of GKLF, we performed in vivo competition experiments using expression constructs containing either wild-type or mutated E1A protein. As shown in Figure 4A, wild-type E1A (competitor 1) potently inhibited transactivation by the GAL4-GKLF(1-109) construct in a dose-dependent manner. Similarly, a mutated E1A construct that contained a deletion in its conserved region 2 (E1ADeltaCR2; competitor 3) was able to inhibit transactivation by the N-terminal 109 amino acids of GKLF (Fig. 4C). In contrast, another mutated E1A that contained a deletion in the conserved region 1 (E1ADeltaCR1; competitor 2) failed to inhibit GKLF's ability to transactivate (Fig. 4B). These results indicate that E1A is a potent inhibitor of transactivation by GKLF and that the conserved region 1 of E1A exerts this inhibitory effect.
###end p 35
###begin p 36
###xml 74 76 74 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c45">45</xref>
###xml 77 79 77 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c54">54</xref>
###xml 80 82 80 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c55">55</xref>
###xml 273 275 273 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c46">46</xref>
###xml 276 278 276 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c47">47</xref>
###xml 288 289 288 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd222f5">5</xref>
The conserved region 1 of E1A has previously been shown to bind p300/CBP (45,54,55). It is therefore possible that p300/CBP may mediate transactivation by GKLF. To determine this, we performed co-transfection experiments using expression constructs containing p300 or CBP (46,47). Figure 5 shows that both p300 and CBP were able to reverse the inhibition of GKLF's transactivation by E1A in a dose-dependent fashion. These findings suggest that p300/CBP are indeed involved in mediating the transactivating activity by GKLF.
###end p 36
###begin title 37
GKLF and CBP physically interact with each other
###end title 37
###begin p 38
###xml 161 163 161 163 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 185 193 185 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 302 303 302 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd222f6">6</xref>
E1A binds to p300/CBP. This raises the possibility that GKLF may also physically interact with p300/CBP. We therefore performed GST pull-down experiments using [35S]methionine-labeled, in vitro synthesized GKLF and GST fusion proteins containing various segments of the CBP protein. As shown in Figure 6, GKLF was recovered from the eluants when it was first incubated with GST-CBP2 (lane 5) and GST-CBP3 (lane 6), with CBP2 exhibiting a higher binding affinity. In contrast, GKLF failed to interact with GST-CBP1 (lane 4) or GST alone (lane 3). Similarly, no activity was recovered from the beads when no GST proteins were present in the initial incubation (lane 2). These results indicate that GKLF specifically binds to CBP and that this binding occurs in at least two different regions of CBP.
###end p 38
###begin p 39
###xml 87 94 87 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 186 188 186 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c47">47</xref>
###xml 250 252 250 252 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 462 463 462 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd222f7">7</xref>
###xml 792 794 792 794 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 1224 1231 1224 1231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 150 153 <span type="species:ncbi:12814?0.7497633322814768|species:ncbi:11886?0.2234143262858946|species:ncbi:12331?0.0041022404544020195">RSV</span>
The interaction between GKLF and CBP was further examined by co-immunoprecipitation of in vivo labeled proteins. COS-1 cells were co-transfected with RSV-CBP tagged with the HA epitope (47) and PMT3 or PMT3-GKLF, and then metabolically labeled with [35S]methionine. Lysates from transfected cells were immunoprecipitated with pre-immune serum, anti-GKLF serum or anti-HA antibodies, and the precipitated materials resolved by autoradiography. As shown in Figure 7, the anti-GKLF serum precipitated GKLF only in cells transfected with PMT3-GKLF (lane 5) but not in those with PMT3 (lane 2). Similarly, anti-HA antibodies precipitated a high-molecular-weight protein likely representing the HA-tagged CBP in transfected cells (lanes 3 and 6). Importantly, anti-HA antibodies also precipitated [35S]methionine-labeled GKLF in PMT3-GKLF-transfected cells (lane 6) but not in PMT3-transfected cells (lane 3). Moreover, when similar co-immunoprecipitation experiments were performed on the two point mutant proteins that involved the acidic residues of GKLF, anti-HA antibodies could no longer precipitate either GKLF mutant (lanes 9 and 11). These results strongly suggest that a physical interaction between GKLF and CBP occurs in vivo, and that the two clusters of acidic residues in the N-terminus of GKLF are crucial for this interaction.
###end p 39
###begin title 40
Acidic residues are required for the growth-suppressing effect of GKLF
###end title 40
###begin p 41
###xml 112 114 112 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c23">23</xref>
###xml 251 253 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c48">48</xref>
###xml 300 301 300 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd222f8">8</xref>
###xml 693 694 693 694 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 727 728 727 728 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
###xml 741 742 741 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd222f8">8</xref>
###xml 1027 1028 1027 1028 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="gkd222f8">8</xref>
GKLF is a potent inhibitor of cell growth as demonstrated by previous studies involving transient transfection (23). In the present study we used an independent method to corroborate the growth-suppressing effect of GKLF-the colony suppression assay (48) that is based on stable transfection. Figure 8A shows that while cells transfected with the PMT3 control plasmid and a puromycin resistance-containing plasmid led to the formation of a large number of puromycin-resistant colonies, those transfected with PMT3-GKLF and the resistant marker had far fewer. The degree of colony suppression by GKLF was slightly over 75% as compared to vector alone, which represents a significant reduction (P < 0.005 by two-tailed Students' t-test) (Fig. 8B). These results suggest that expression of GKLF hindered cell growth, therefore preventing the formation of colonies. Importantly, the two point mutants of GKLF that abolished the transactivating and interacting abilities of GKLF completely failed to suppress colony formation (Fig. 8A and B). We conclude that the same acidic residues in the N-terminus of GKLF are implicated in at least three of its biological activities including transactivation, protein-protein interaction and growth suppression.
###end p 41
###begin title 42
DISCUSSION
###end title 42
###begin p 43
###xml 86 88 86 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c23">23</xref>
###xml 192 194 192 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c25">25</xref>
###xml 403 405 403 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c23">23</xref>
###xml 406 408 406 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c27">27</xref>
###xml 556 558 556 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c26">26</xref>
###xml 687 689 687 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c24">24</xref>
###xml 690 692 690 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c25">25</xref>
###xml 693 695 693 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c27">27</xref>
###xml 696 698 696 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c36">36</xref>
###xml 699 701 699 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c39">39</xref>
###xml 758 760 758 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c24">24</xref>
###xml 761 763 761 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c26">26</xref>
###xml 764 766 764 766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c39">39</xref>
###xml 823 825 823 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c29">29</xref>
###xml 964 966 964 966 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c26">26</xref>
###xml 967 969 967 969 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c39">39</xref>
###xml 999 1001 999 1001 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c24">24</xref>
###xml 1002 1004 1002 1004 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c26">26</xref>
###xml 1005 1007 1005 1007 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c36">36</xref>
###xml 1131 1133 1131 1133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c27">27</xref>
###xml 137 142 <span type="species:ncbi:10090">mouse</span>
GKLF was first identified 3 years ago based on low-stringency cDNA library screening (23) and polymerase chain reaction amplification of mouse embryonic cDNA with degenerate oligonucleotides (25). Although the definitive physiological functions of GKLF have yet to be established, studies suggest that it is involved in the regulation of proliferation and differentiation of certain epithelial tissues (23-27). One important role that GKLF plays is to maintain a barrier function of the skin as demonstrated by recent experiments involving gene targeting (26). Recent studies have also delineated some of the biochemical properties of GKLF including the DNA sequences to which it binds (24,25,27,36,39), the potential target genes subject to its regulation (24,26,39) and the signals required for its nuclear localization (29). In addition, GKLF was shown to exhibit a dual mechanism in modulating transcription, acting as a repressor under certain circumstances (26,39) and an activator in others (24-26,36). Moreover, studies involving deletional mutagenesis showed that GKLF contains distinct repressive and activating domains (27). Taken together, these findings suggest that the mechanism of action of GKLF is complex. The current study thus provides new and detailed information on the mechanism of transactivation by GKLF from a structural-functional perspective.
###end p 43
###begin p 44
###xml 242 243 242 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c7">7</xref>
###xml 244 245 244 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c8">8</xref>
###xml 258 259 258 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c9">9</xref>
###xml 260 262 260 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c10">10</xref>
###xml 284 286 284 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c11">11</xref>
###xml 287 289 287 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c13">13</xref>
###xml 376 377 376 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c7">7</xref>
###xml 440 441 440 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c8">8</xref>
###xml 581 583 581 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c56">56</xref>
###xml 674 676 674 676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c23">23</xref>
Various mechanisms have been shown to be involved in the activation of transcription by eukaryotic transcription factors. The domains responsible for transactivation often belong to one or more of three sequences that are rich in glutamates (7,8), prolines (9,10) or acidic residues (11-13). Among the Kruppel-related proteins, Sp1 uses glutamate-rich domains for activation (7) while NGFI-A uses all three types of domains for activation (8). The transactivation domain of BTEB2, which exhibits significant homology to GKLF in the zinc finger region, is rich in proline residues (56). Although the primary amino acid sequence of GKLF is also very rich in prolines (12.8%) (23), our results indicate that these residues are not essential for transactivation by GKLF. Instead, certain acidic amino acid residues are required. These studies therefore demonstrate a functional heterogeneity in the mechanisms of transactivation by the Kruppel family of related proteins.
###end p 44
###begin p 45
###xml 173 175 173 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c23">23</xref>
###xml 176 178 176 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c29">29</xref>
###xml 332 334 332 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c49">49</xref>
###xml 566 568 566 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c49">49</xref>
###xml 616 618 616 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c53">53</xref>
###xml 714 716 714 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c53">53</xref>
Be that as it may, there is a remarkable degree of similarity in the mechanism of transactivation between GKLF and EKLF, a member of the GKLF subfamily of Kruppel proteins (23,29). The activation domain of EKLF has been localized to between amino acid residues 20 and 124, a region that is rich in both acidic and proline residues (49). Protein-protein interaction has also been shown to be important in the ability of EKLF to activate transcription and evidence suggests that such interaction is mediated by acidic residues localized within the N-terminus of EKLF (49). EKLF physically interacts with p300 and CBP (53). In transient transfection assays the addition of p300/CBP increased transactivation by EKLF (53). Thus, despite a difference in the primary sequence between the activation domains of GKLF and EKLF, there appears to be a significant degree of functional conservation in the mechanism by which the two proteins activate transcription.
###end p 45
###begin p 46
###xml 101 103 101 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c57">57</xref>
###xml 231 233 231 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c50">50</xref>
###xml 234 236 234 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c51">51</xref>
###xml 344 346 344 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c58">58</xref>
###xml 347 349 347 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c59">59</xref>
###xml 482 484 482 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c50">50</xref>
###xml 485 487 485 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c57">57</xref>
###xml 812 814 812 814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c60">60</xref>
###xml 952 954 952 954 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c47">47</xref>
###xml 955 957 955 957 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c61">61</xref>
###xml 1239 1241 1239 1241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c15">15</xref>
###xml 1393 1395 1393 1395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c62">62</xref>
###xml 1533 1535 1533 1535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c63">63</xref>
p300 and CBP belong to the family of proteins that exhibit histone acetyltransferase (HAT) activity (57). They function to stimulate transcription of specific promoters following their recruitment by specific DNA-binding proteins (50,51). The HAT activity within p300/CBP is responsible, at least in part, for this transcriptional stimulation (58,59). Numerous studies have demonstrated that p300/CBP may play a key role in the regulation of cell proliferation and differentiation (50,57). For example, p300 has been shown to physically interact with the myogenic transcription factor MyoD in differentiating myocytes. This interaction is necessary for both MyoD-induced activation of muscle-specific gene transcription and cell cycle arrest due to an up-regulation of the cyclin-dependent kinase inhibitor p21 (60). p300/CBP have also been shown to interact with the tumor suppressor p53, thereby modulating the cell cycle regulatory activity of p53 (47,61). Moreover, there is considerable evidence to suggest that interaction between the adenoviral oncoprotein E1A and p300/CBP is important for the biological effects of E1A including regulation of transcription, suppression of differentiation and immortalization of cells in culture (15). In the context of gut epithelial differentiation, expression of CBP has been associated with terminal differentiation of a model enterocyte, Caco-2 (62). Furthermore, CBP interacts with Cdx2, a homeodomain protein purportedly implicated in effecting intestinal epithelial differentiation (63). Taking into view the potential role of GKLF in regulating cell proliferation and differentiation, it is very possible that p300/CBP are also an important component that mediates some of GKLF's biological activities.
###end p 46
###begin p 47
###xml 108 110 108 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="gkd222c23">23</xref>
Using transient transfection assays, we previously showed that GKLF is a potent inhibitor of DNA synthesis (23). This inhibitory effect was substantiated in the present study by the colony suppression assay that is based on stable transfection. Importantly, point mutations in GKLF abolishing the transactivating activity of GKLF also abolished its growth-inhibitory effect. Thus, transactivation is an essential element of GKLF's biological functions. The significance of this finding is further increased by the fact that the same acidic residues are crucial for interaction with CBP. Consequently, these domains likely represent the convergence of several important aspects of GKLF's activities, including transactivation, protein-protein interaction and growth suppression. Our study therefore provides strong evidence for an important structural and functional correlation among the various biological effects of GKLF.
###end p 47
###begin title 48
Figures and Tables
###end title 48
###begin p 49
###xml 208 209 204 205 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 226 227 222 223 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 379 389 375 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">effector V</italic>
###xml 429 430 425 426 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 568 579 564 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink">effectors 7</italic>
###xml 584 585 580 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink">8</italic>
###xml 634 635 630 631 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 78 93 <span type="species:ncbi:10029">Chinese hamster</span>
 Localization of the transactivation domain of GKLF by the GAL4 fusion assay. Chinese hamster ovary (CHO) cells were co-transfected with 5 microg/10 cm dish each of the indicated effector construct and the pG5TKLUC reporter. (A) Mean fold-induction in luciferase activity by the respective effector over that by the control vector containing only the DNA-binding domain of GAL4 (effector V). Bars represent standard deviations. (B) Schematic presentation of the various GAL4 fusion effector constructs. The point mutants involving the two clusters of acidic residues, effectors 7 and 8, are drawn as E*E*E* and D*D*D*, respectively. (C) Amino acid sequence between residues 91 and 110 of GKLF and identifies the mutagenized residues. All luciferase activities were standardized to the internal control beta-galactosidase activities. Data represent the means of four independent experiments, each performed in duplicate.
###end p 49
###begin p 50
###xml 158 160 154 156 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1b</sub>
###xml 265 276 261 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">effectors 1</italic>
###xml 277 278 273 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">7</italic>
###xml 300 301 296 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">V</italic>
###xml 311 312 307 308 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 384 385 380 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 393 394 389 390 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 459 469 455 465 <italic xmlns:xlink="http://www.w3.org/1999/xlink">effector 6</italic>
###xml 525 535 521 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink">effector 7</italic>
 Localization of the transactivation domain of GKLF using its cognate binding site. CHO cells were co-transfected with 5 microg/10 cm dish each of the TDAx2-E1bTATALUC reporter and the respective effector constructs containing various regions or mutations of GKLF (effectors 1-7) or the vector PMT3 (V) alone. (A) Means of fold-induction in reporter activity over that of the vector (n = 4). (B) Schematic of the various effector constructs. The three E*s in effector 6 indicate the mutated glutamate residues and the D*s in effector 7 indicate the three mutated aspartate residues.
###end p 50
###begin p 51
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vivo</italic>
###xml 112 113 108 109 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 387 388 379 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 409 410 401 402 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 417 418 409 410 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 425 426 417 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 447 448 439 440 <bold xmlns:xlink="http://www.w3.org/1999/xlink">C</bold>
###xml 451 452 443 444 <bold xmlns:xlink="http://www.w3.org/1999/xlink">F</bold>
In vivo competition assays of transactivation by GKLF. CHO cells were transfected with 2 microg/10 cm dish of pG5TKLUC, 0.5 microg/10 cm dish of GAL4-GKLF(1-109) and increasing amounts of the various competitor PMT3 constructs in fold-excess relative to that of GAL4-GKLF(1-109) as indicated. The relative luciferase activity of cells that received no competitor DNA was chosen as 100%. n = 6 in experiments (A) and (B), and n = 4 in experiments (C)-(F).
###end p 51
###begin p 52
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vivo</italic>
###xml 133 134 129 130 <sub xmlns:xlink="http://www.w3.org/1999/xlink">5</sub>
###xml 426 427 418 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 222 225 <span type="species:ncbi:12814?0.7497633322814768|species:ncbi:11886?0.2234143262858946|species:ncbi:12331?0.0041022404544020195">RSV</span>
In vivo competition of GKLF's transactivation by E1A-expressing constructs. CHO cells were transfected with 2 microg/10 cm dish of pG5TKLUC, 0.5 microg/10 cm dish of GAL4-GKLF(1-109) and increasing amounts of a competitor RSV construct containing either wild-type or mutated E1A in fold-excess relative to that of GAL4-GKLF(1-109). The relative luciferase activity of cells that received no competitor DNA was chosen as 100%. n = 3 in all experiments. CR indicates conserved region.
###end p 52
###begin p 53
###xml 399 400 387 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 207 210 <span type="species:ncbi:12814?0.7497633322814768|species:ncbi:11886?0.2234143262858946|species:ncbi:12331?0.0041022404544020195">RSV</span>
###xml 260 263 <span type="species:ncbi:12814?0.7497633322814768|species:ncbi:11886?0.2234143262858946|species:ncbi:12331?0.0041022404544020195">RSV</span>
###xml 284 287 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
 p300/CBP reverses the inhibitory effect of E1A on transactivation by GKLF. CHO cells were transfected with 2 microg/10 cm dish of pG5TKLUC, 0.5 microg/10 cm dish of GAL4-GKLF(1-109), 1 microg/10 cm dish of RSV-E1A except for lane 1, and increasing amounts of RSV-p300 (lanes 3-5) or CMV-CBP (lanes 6-8) at the indicated concentrations. The relative luciferase activity of lane 1 was taken as 100%. n = 4.
###end p 53
###begin p 54
###xml 31 39 31 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro</italic>
###xml 41 43 41 43 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
 GST pull-down of GKLF by CBP. In vitro [35S]methionine-labeled GKLF was incubated with recombinant GST fusion proteins containing three different segments of CBP (lanes 4-6) or GST only (lane 3), followed by the addition of glutathione-Sepharose 4B beads. After thoroughly washing the beads with a detergent-containing solution, the bound proteins were eluted with reduced glutathione, resolved by denaturing PAGE and visualized by autoradiography. Lane 1, input GKLF, which represents 10% of the protein used in the pull-down experiments; lane 2, no input GST proteins.
###end p 54
###begin p 55
###xml 335 337 331 333 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 350 357 346 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 104 107 <span type="species:ncbi:12814?0.7497633322814768|species:ncbi:11886?0.2234143262858946|species:ncbi:12331?0.0041022404544020195">RSV</span>
 Co-immunoprecipitation of GKLF and CBP. COS-1 cells were transfected with 10 microg/10 cm dish each of RSV-HA-CBP and PMT3 (lanes 1-3), wild-type (WT) PMT3-GKLF (lanes 4-6), PMT3-GKLF(E93/95/96V) (E*E*E*; lanes 7-9), or PMT3-GKLF(D99/102/104V) (D*D*D*; lanes 10-12). Twenty-four hours later, proteins were metabolically labeled with [35S]methionine in vivo. Cells were then lysed and the lysates incubated with pre-immune (PI) serum, anti-GKLF serum (alphaGKLF) or anti-HA antibodies (alphaHA). The immune complex was precipitated with protein A-Sepharose beads and resolved by gel electrophoresis following repeated washings of the beads. The asterisks identify HA-CBP. dagger, Wild-type GKLF; double dagger, the mutant GKLF.
###end p 55
###begin p 56
###xml 333 334 325 326 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A</bold>
###xml 338 339 330 331 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B</bold>
###xml 424 425 416 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 458 459 450 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t</italic>
 Colony suppression assays of GKLF. Rat1a cells were transfected with 10 microg/10 cm dish of the stated PMT3 constructs and 0.25 microg/10 cm dish of pBabe Puro (48). Two days following transfection, cells were fed media containing puromycin for 2 weeks. Resistant colonies of cells were visualized by staining with methylene blue (A). (B) Mean number of colonies for four dishes of cells transfected with each construct. *P < 0.005 by two-tailed Students' t-test between PMT3- and PMT3-GKLF-transfected cells.
###end p 56
###begin title 57
ACKNOWLEDGEMENTS
###end title 57
###begin p 58
###xml 393 404 <span type="species:ncbi:9606">participant</span>
We thank Drs C. V. Dang, A. B. Leiter, T. Kouzarides, R. H. Goodman and R. G. Roeder for plasmids, and Channing Mahatan for technical assistance. This work was in part supported by grants DK44484, DK52230 and CA84197 (to V.W.Y.) from the National Institutes of Health. H.T.-T. was a recipient of a National Research Service award from the National Institutes of Health (DK09492). J.M.J. was a participant of the Minority Summer Internship Program of the Johns Hopkins University School of Medicine and a recipient of a Student Research Fellowship Award from the American Digestive Health Foundation.
###end p 58
###begin title 59
REFERENCES
###end title 59

